Federal regulators are raising new concerns about side effects linked to Ozempic and similar medications, widely used for diabetes and weight loss.
The rapid rise of medications such as Ozempic and Wegovy has transformed diabetes care and fueled the booming weight-loss drug market. But U.S. health regulators are now raising fresh concerns about safety reporting and potential side effects tied to these widely used treatments.
In March 2026, the U.S. Food and Drug Administration issued a warning letter to Novo Nordisk, stating the company failed to properly report certain serious adverse events associated with the drugs, including reports of two deaths and one suicide.
The medications contain semaglutide, part of a class of drugs known as GLP-1 receptor agonists. These medications mimic a hormone that helps regulate blood sugar and appetite. They have been widely prescribed for type 2 diabetes and increasingly used for weight management.
However, federal regulators say several potentially serious side effects require continued monitoring.
According to the U.S. Food and Drug Administration, safety labels for semaglutide drugs have been updated in recent years to include a range of risks reported after the medications reached the market.
Among the key concerns:
• Severe gastrointestinal complications: The FDA added warnings about ileus, a dangerous intestinal blockage that can prevent food from moving through the digestive tract.
• Gastroparesis: Some patients have reported stomach paralysis, a condition that delays or stops the stomach from emptying properly.
• Pulmonary aspiration risk: Label updates in 2024 warned that patients undergoing anesthesia may face a higher risk of food regurgitation entering the lungs.
• Thyroid tumor warning: Ozempic carries the FDA’s strongest safety alert, known as a boxed warning, about the potential risk of thyroid C-cell tumors.
Regulators are also reviewing reports of suicidal thoughts or behaviors among patients taking GLP-1 medications.
Data from the FDA’s adverse-event reporting system has linked semaglutide-based drugs to more than 160 reported deaths and over 10,000 serious adverse events, including hospitalizations.
Health experts caution that these reports do not prove the medication directly caused the outcome, but they often serve as early warning signals that require further investigation.
Extra Warning About Compounded Versions
The FDA has also issued alerts about compounded semaglutide, versions of the drug produced by pharmacies during shortages. These products are not FDA-approved, and regulators say some have been linked to overdoses and hospitalizations.
Doctors emphasize that Ozempic and related medications can provide major benefits when used appropriately. Still, experts say patients should speak with their healthcare provider about risks and report unusual symptoms immediately.
“These medications can be effective tools,” regulators say, “but patient safety depends on accurate reporting, monitoring and informed use.”
As use of GLP-1 drugs continues to surge across the United States, federal regulators say ongoing surveillance will be critical to ensure their benefits outweigh potential risks.
Weight Regain After Stopping GLP-1 Drugs: What Ozempic’s Long-Term Science Now Shows
